The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
Open accessAbstract
Neuroinflammation is a host-defense mechanism associated with restoration of normal structure and function of the brain and neutralization of an insult. Increasing neuropathological and biochemical evidence from the brains of individuals with Parkinson’s disease (PD) provides strong evidence for activation of neuroinflammatory pathways. Microglia, the resident innate immune cells, may play a major role in the inflammatory process of the diseased brain of patients with PD. Although microglia forms the first line of defense for the neural parenchyma, uncontrolled activation of microglia may directly affect neurons by releasing various molecular mediators such as inflammatory cytokines (tumor necrosis factor-α, interleukin [IL]-6, and IL-1 β), nitric oxide, prostaglandin E2, and reactive oxygen and nitrogen species. Moreover, recent studies have reported that activated microglia phagocytose not only damaged cell debris but also intact neighboring cells. This phenomenon further supports their active participation in self-enduring neuronal damage cycles. As the relationship between PD and neuroinflammation is being studied, there is a realization that both cellular and molecular mediators are most likely assisting pathological processes leading to disease progression. Here, we discuss mediators of neuroinflammation, which are known activators released from damaged parenchyma of the brain and result in neuronal degeneration in patients with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 1×
“complement system leads to a cascade of events ultimately leading to the destruction of cell surface with three different recognized pathways, which share a common juncture at the level of the C3 protein [140, 141].”
BackgroundHeterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“The SN is relatively rich inmicroglia comparedwith other brain regions [34, 35].”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759
Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing
Hampton, M. B., Kettle, A. J., & Winterbourn, C. C. (1998) · Blood · doi:10.1182/blood.v92.9.3007 · Cited by 1,652
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 1×
“Membrane-bound neuronal inhibitory signals consist of several molecules from the immunoglobulin superfamily including CD200 [50], CD22, and CD47, which are expressed or secreted by neurons that bind to receptors on microglia [48, 51, 52].”
BackgroundMolecular profile of reactive astrocytes—Implications for their role in neurologic disease
Eddleston, M., & Mucke, L. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90380-x · Cited by 1,431
Astrocyte Control of Synaptic Transmission and Neurovascular Coupling
Haydon, P. G., & Carmignoto, G. (2006) · Physiological Reviews · doi:10.1152/physrev.00049.2005 · Cited by 1,323
Astrocytes are active players in cerebral innate immunity
Farina, C., Aloisi, F., & Meinl, E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.01.005 · Cited by 1,304
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs
Olson, J. K., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3916 · Cited by 1,215
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“However, resting microglial cells quickly proliferate, become hypertrophic, and persistently increase expression of a large number of marker molecules such as CD11b, CD68, and MHC-I and II molecules [28] and are further transformed to macrophage-like cells in patients with PD [11, 29, 30].”
BackgroundBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200)
Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B., Homola, M. E., Streit, W. J., Brown, M. H., et al. (2000) · Science · doi:10.1126/science.290.5497.1768 · Cited by 1,022
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures
Dawson, V., Dawson, T., Bartley, D., Uhl, G., & Snyder, S. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-06-02651.1993 · Cited by 1,014
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 957
Kim, W.-G., Mohney, R. P., Wilson, B., Jeohn, G.-H., Liu, B., & Hong, J.-S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 878
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis
Koizumi, S., Shigemoto-Mogami, Y., Nasu-Tada, K., Shinozaki, Y., Ohsawa, K., Tsuda, M., Joshi, B. V., Jacobson, K. A., Kohsaka, S., & Inoue, K. (2007) · Nature · doi:10.1038/nature05704 · Cited by 802
Neuronal ‘On’ and ‘Off’ signals control microglia
Biber, K., Neumann, H., Inoue, K., & Boddeke, H. W. G. M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.08.007 · Cited by 787
Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite
van der Vliet, A., Eiserich, J. P., Halliwell, B., & Cross, C. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7617 · Cited by 780
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
Teismann, P., Tieu, K., Choi, D.-K., Wu, D.-C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0837397100 · Cited by 660
Self-citationNeuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Inflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 625
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
What is the blood–brain barrier (not)?
Bechmann, I., Galea, I., & Perry, V. H. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.11.007 · Cited by 520
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510
Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503
P2X7 receptor inhibition improves recovery after spinal cord injury
Wang, X., Arcuino, G., Takano, T., Lin, J., Peng, W. G., Wan, P., Li, P., Xu, Q., Liu, Q. S., Goldman, S. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1082 · Cited by 494
Glutathione peroxidase, glial cells and Parkinson's disease
Damier, P., Hirsch, E. C., Zhang, P., Agid, Y., & Javoy-Agid, F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90175-f · Cited by 466
Modulation of inflammation in brain: A matter of fat
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04371.x · Cited by 460
Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease
Banati, R. B., Daniel, S. E., & Blunt, S. B. (1998) · Movement Disorders · doi:10.1002/mds.870130205 · Cited by 431
The SIRP family of receptors and immune regulation
Barclay, A. N., & Brown, M. H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1859 · Cited by 426
Neuronal CXCL10 Directs CD8 + T-Cell Recruitment and Control of West Nile Virus Encephalitis
Klein, R. S., Lin, E., Zhang, B., Luster, A. D., Tollett, J., Samuel, M. A., Engle, M., & Diamond, M. S. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11457-11466.2005 · Cited by 424
Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, E. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 408
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Neuroinflammatory processes in Parkinson's disease
Hunot, S., & Hirsch, E. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 398
Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363
Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Pisarev, V. M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001376 · Cited by 362
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Control of glial immune function by neurons
Neumann, H. (2001) · Glia · doi:10.1002/glia.1108 · Cited by 319
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Cytokines in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6284-2_12 · Cited by 308
Teismann, P., & Ferger, B. (2001) · Synapse · doi:10.1002/1098-2396(200102)39:2<167::aid-syn8>3.0.co;2-u · Cited by 306
Neuroinflammatory processes in Parkinson's disease
Hirsch, E. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 296
Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration
Ben‐Shachar, D., Zuk, R., & Glinka, Y. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020718.x · Cited by 287
Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy
Qian, L., Flood, P. M., & Hong, J.-S. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0428-1 · Cited by 287
Zecca, L., Zucca, F. A., Wilms, H., & Sulzer, D. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.009 · Cited by 264
Kim, Y. S., Kim, S. S., Cho, J. J., Choi, D. H., Hwang, O., Shin, D. H., Chun, H. S., Beal, M. F., & Joh, T. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4346-04.2005 · Cited by 258
Self-citationRole of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys
Miklossy, J., Doudet, D. D., Schwab, C., Yu, S., McGeer, E. G., & McGeer, P. L. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255
The parkinsonian toxin MPTP: action and mechanism
Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Vukosavic, S., & Almer, G. (2000) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2000-00132 · Cited by 252
Inflammation and Adaptive Immunity in Parkinson's Disease
Mosley, R. L., Hutter-Saunders, J. A., Stone, D. K., & Gendelman, H. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 247
Sánchez‐Pernaute, R., Ferree, A. W., Cooper, O., Yu, M., Brownell, A., & Ole Isacson, A. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-6 · Cited by 229
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227
Astrocytes and Therapeutics for Parkinson's Disease
Rappold, P. M., & Tieu, K. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.001 · Cited by 226
Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal
Schapira, A. H. V. (1994) · Movement Disorders · doi:10.1002/mds.870090202 · Cited by 219
Van BEEK, J., ELWARD, K., & GASQUE, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03138.x · Cited by 218
Wright, G. J., Jones, M., Puklavec, M. J., Brown, M. H., & Barclay, A. N. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01163.x · Cited by 217
Microglia in neurodegeneration: Molecular aspects
Gebicke‐Haerter, P. J. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1120 · Cited by 212
Taylor, D. L., Diemel, L. T., & Pocock, J. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02150.2003 · Cited by 202
Kim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y. J., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-5865com · Cited by 199
Self-citationCNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease?
Rezai-Zadeh, K., Gate, D., & Town, T. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9166-2 · Cited by 197
Inflammation in Parkinson's disease.
McGeer, P. L., Yasojima, K., & McGeer, E. G. (2001) · PubMed · Cited by 197
Alpha‐Synuclein Stimulation of Astrocytes: Potential Role for Neuroinflammation and Neuroprotection
Lee, H.-J., Kim, C., & Lee, S.-J. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.4.12809 · Cited by 194
COX‐2 and Neurodegeneration in Parkinson's Disease
TEISMANN, P., VILA, M., CHOI, D. ‐., TIEU, K., WU, D. C., JACKSON‐LEWIS, V., & PRZEDBORSKI, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07482.x · Cited by 178
Self-citationThrombin‐Induced Activation of Cultured Rodent Microglia
Möller, T., Hanisch, U., & Ransom, B. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751539.x · Cited by 175
Neuroinflammation in Parkinson’s Disease
Lee, J.-K., Tran, T., & Tansey, M. G. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9176-0 · Cited by 171
Ezcurra, A. L. D. L., Chertoff, M., Ferrari, C. C., Graciarena, M., & Pitossi, F. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.018 · Cited by 164
Sugama, S., Yang, L., Cho, B. P., DeGiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., & Joh, T. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04085-4 · Cited by 164
Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 160
Zhang, W., Dallas, S., Zhang, D., Guo, J., Pang, H., Wilson, B., Miller, D. S., Chen, B., Zhang, W., McGeer, P. L., et al. (2007) · Glia · doi:10.1002/glia.20532 · Cited by 160
The Role of Microglia in Paraquat-Induced Dopaminergic Neurotoxicity
Wu, X.-F., Block, M. L., Zhang, W., Qin, L., Wilson, B., Zhang, W.-Q., Veronesi, B., & Hong, J.-S. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.654 · Cited by 158
Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients
Migliore, L., Petrozzi, L., Lucetti, C., Gambaccini, G., Bernardini, S., Scarpato, R., Trippi, F., Barale, R., Frenzilli, G., Rodilla, V., et al. (2002) · Neurology · doi:10.1212/wnl.58.12.1809 · Cited by 157
Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity
Limatola, C., Lauro, C., Catalano, M., Ciotti, M. T., Bertollini, C., Di Angelantonio, S., Ragozzino, D., & Eusebi, F. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.03.023 · Cited by 153
de Jong, E. K., Dijkstra, I. M., Hensens, M., Brouwer, N., van Amerongen, M. J., Liem, R. S. B., Boddeke, H. W. G. M., & Biber, K. P. H. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1019-05.2005 · Cited by 152
Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease
Stone, D. K., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2460 · Cited by 151
Karunakaran, S., Saeed, U., Mishra, M., Valli, R. K., Joshi, S. D., Meka, D. P., Seth, P., & Ravindranath, V. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4511-08.2008 · Cited by 150
Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.
Loeffler, D. A., Camp, D. M., & Conant, S. B. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-29 · Cited by 150
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143
Increased cerebrospinal fluid concentration of nitrite in Parkinsonʼs disease
Qureshi, G. A., Baig, S., Bednar, I., Södersten, P., Forsberg, G., & Sidén, Å. (1995) · Neuroreport · doi:10.1097/00001756-199508000-00013 · Cited by 135
Innate Inflammation in Parkinson's Disease
Perry, V. H. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009373 · Cited by 132
Increase in Peripheral CD4 Bright+ CD8 Dull+ T Cells in Parkinson Disease
Hisanaga, K., 浅黄美沙, Itoyama, Y., & Iwasaki, Y. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1580 · Cited by 131
Wang, Y., Hancock, A. M., Bradner, J. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D. R., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.006 · Cited by 128
Parkinson's disease in the nuclear age of neuroinflammation
Nolan, Y. M., Sullivan, A. M., & Toulouse, A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.003 · Cited by 126
Kurkowska‐Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-1999-1289 · Cited by 125
Neuronal Control of the Immune Response in the Central Nervous System
Neumann, H., & Wekerle, H. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199801000-00001 · Cited by 125
Hayley, S. P., Crocker, S. J., Smith, P. D., Shree, T., Jackson-Lewis, V. R., Przedborski, S., Mount, M., Slack, R. S., Anisman, H., & Park, D. S. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4564-03.2004 · Cited by 125
Koppula, S., Kumar, H., Kim, I. S., & Choi, D. (2012) · Mediators of Inflammation · doi:10.1155/2012/823902 · Cited by 117
Self-citationMPP + ‐induced COX‐2 activation and subsequent dopaminergic neurodegeneration
Wang, T., Pei, Z., Zhang, W., Liu, B., Langenbach, R. I., Lee, C., Wilson, B. C., Reece, J. M., Miller, D. S., & Hong, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2457fje · Cited by 114
Li, Q., Block, M. L., Wei, S., Lin, C., Reece, J. M., Pang, H., Wilson, B. C., Hong, J., & Flood, P. M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106351 · Cited by 110
γδ+ T cells are increased in patients with Parkinson's disease
Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., Olsson, T. P., & Link, H. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90154-6 · Cited by 108
Depboylu, C., Stricker, S., Ghobril, J.-P., Oertel, W. H., Priller, J., & Höglinger, G. U. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.020 · Cited by 105
Yin and Yang: complement activation and regulation in Alzheimer’s disease
Shen, Y., & Meri, S. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.08.001 · Cited by 101
Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells
Ciesielski-Treska, J., Ulrich, G., Taupenot, L., Chasserot‐Golaz, S., Corti, A., Aunis, D., & Bader, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14339 · Cited by 100
COX‐2 in the neurodegenerative process of Parkinson's disease
Teismann, P. (2012) · BioFactors · doi:10.1002/biof.1035 · Cited by 95
Taupenot, L., Ciesielski-Treska, J., Ulrich, G., Chasserot‐Golaz, S., Aunis, D., & Bader, M. F. (1996) · Neuroscience · doi:10.1016/0306-4522(96)83172-1 · Cited by 94
Depboylu, C., Schafer, M. K.-H., Arias-Carrión, Ó., Oertel, W. H., Weihe, E., & Höglinger, G. U. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820805b9 · Cited by 91
Tsai, S.-J., Chao, C., & Yin, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.171 · Cited by 88
Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients
Petrozzi, L., Lucetti, C., Scarpato, R., Gambaccini, G., Trippi, F., Bernardini, S., Dotto, P. D., Migliore, L., & Bonuccelli, U. (2002) · Neurological Sciences · doi:10.1007/s100720200087 · Cited by 87
Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis
McGeer, E. G., & McGeer, P. L. (2005) · BioDrugs · doi:10.2165/00063030-200519010-00004 · Cited by 84
Chow, Y.-L., Lee, K.-H., Vidyadaran, S., Lajis, N. H., Akhtar, M. N., Israf, D. A., & Ahmad, S. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.01.009 · Cited by 83
Gordon, R., Anantharam, V., Kanthasamy, A. G., & Kanthasamy, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-82 · Cited by 83
Koharudin, L. M. I., Liu, H., Maio, R. D., Kodali, R. B., Graham, S. H., & Gronenborn, A. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002295107 · Cited by 80
Innate Immunity, Local Inflammation, and Degenerative Disease
McGeer, P. L., & McGeer, E. G. (2002) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2002.29.re3 · Cited by 79
Fas and Fas‐L expression in Huntington's disease and Parkinson's disease
Ferrer, I., Blanco, R., Cutillas, B., & Ambrosio, S. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.00267.x · Cited by 74
Clinical implications of the involvement of tPA in neuronal cell death
Tsirka, S. E. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050119 · Cited by 71
Chang, R. C. C., Hudson, P., Wilson, B., Haddon, L., & Hong, J.-S. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02255-6 · Cited by 68
Sekiyama, K., Sugama, S., Fujita, M., Sekigawa, A., Takamatsu, Y., Waragai, M., Takenouchi, T., & Hashimoto, M. (2012) · Parkinson s Disease · doi:10.1155/2012/271732 · Cited by 65
COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice
Feng, Z., Li, D., Fung, P. C. W., Pei, Z., Ramsden, D. B., & Ho, S. (2003) · Neuroreport · doi:10.1097/00001756-200310270-00009 · Cited by 65
O’Barr, S. A., & Cooper, N. R. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00291-5 · Cited by 63
The complement system in central nervous system diseases
Rus, H., Cudrici, C. D., David, S., & Niculescu, F. I. (2006) · Autoimmunity · doi:10.1080/08916930600739605 · Cited by 62
Yasuhara, O., Kawamata, T., Aimi, Y., McGeer, E. G., & McGeer, P. L. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90227-5 · Cited by 58
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells
Shamoto‐Nagai, M., Maruyama, W., Akao, Y., Osawa, T., Tribl, F., Gerlach, M., Zucca, F. A., Zecca, L., Riederer, P. F., & Naoi, M. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0211-2 · Cited by 56
PERIPHERAL-TYPE BENZODIAZEPINE BINDING IN ALZHEIMER DISEASE
McGeer, E. G., Singh, E. A., & McGeer, P. L. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802040-00001 · Cited by 49
Activated Immune Cells in Parkinson's Disease
Cao, J., Li, K., & Shen, Y. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9280-9 · Cited by 47
Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia
Yamada, T., McGeer, E. G., Schelper, R. L., Wszołek, Z. K., McGeer, P. L., Pfeiffer, R. F., & Rodnitzky, R. L. (1993) · Neurology Psychiatry and Brain Research · Cited by 44
Przybyłkowski, A. M., Kurkowska‐Jastrzębska, I., Joniec‐Maciejak, I., Ciesielska, A., Członkowska, A., & Członkowski, A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.095 · Cited by 43
Glial Cell Response: A Pathogenic Factor in Parkinson's Disease
Wu, D. C., Tieu, K., Cohen, O. S., Choi, D., Vila, M., Jackson-Lewis, V. R., Teismann, P., & Przedborski, S. (2002) · Journal of NeuroVirology · doi:10.1080/13550280290100905 · Cited by 41
Self-citationEffects of Miglyol 812 on Rats After 4 Weeks of Gavage as Compared with Methylcellulose/Tween 80
Sellers, R. S., Antman, M., Phillips, J. M., Khan, K. N. M., & Furst, S. M. (2005) · Drug and Chemical Toxicology · doi:10.1080/01480540500262839 · Cited by 34
Ko, H. M., Koppula, S., Kim, B.-W., Kim, I. S., Hwang, B. Y., Suk, K., Park, E. J., & Choi, D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.011 · Cited by 31
Self-citationIncreases of pentraxin 3 plasma levels in patients with Parkinson's disease
Lee, H., Choi, J., & Suk, K. (2011) · Movement Disorders · doi:10.1002/mds.23871 · Cited by 28
Immunoregulation of microglial functional properties
Cross, A. K., & Woodroofe, M. N. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1115 · Cited by 28
Growth Promoting and Inhibitory Effects of Glial Cells in the Mammalian Nervous System
Hirsch, S., & Bähr, M. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4685-6_16 · Cited by 27
Choi, D., Koppula, S., Choi, M., & Suk, K. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.525220 · Cited by 25
Self-citationMitochondrial Therapy for Parkinson Disease
Rosenberg, R. N. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1523 · Cited by 14
Parkinsonism and extraocular motor abnormalities with unusual neuropathological findings
Calabrese, V. P., & Hadfield, M. G. (1991) · Movement Disorders · doi:10.1002/mds.870060311 · Cited by 13
Cited by
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
Kempuraj, D., Thangavel, R., Selvakumar, G. P., Zaheer, S., Ahmed, M. E., Raikwar, S. P., Zahoor, H., Saeed, D., Natteru, P. A., Iyer, S., et al. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00216 · Cited by 365
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 351
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Hooten, K. G., Beers, D. R., Zhao, W., & Appel, S. H. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0329-3 · Cited by 275
Wilson, C., & González-Billault, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00381 · Cited by 238
Metadata
- Authors
- More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-12
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2086816316
- Cited by
- 258
- References
- 146
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.